Heritage Trust Co Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Heritage Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,411 shares of the biopharmaceutical company's stock, valued at approximately $1,717,000.

Several other hedge funds also recently made changes to their positions in REGN. MML Investors Services LLC raised its holdings in Regeneron Pharmaceuticals by 13.9% during the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company's stock worth $5,587,000 after buying an additional 648 shares during the period. M&T Bank Corp grew its position in Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company's stock worth $5,761,000 after purchasing an additional 224 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.8% in the third quarter. Coldstream Capital Management Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $1,359,000 after buying an additional 60 shares during the period. Toronto Dominion Bank raised its position in Regeneron Pharmaceuticals by 2.6% during the third quarter. Toronto Dominion Bank now owns 54,719 shares of the biopharmaceutical company's stock valued at $57,523,000 after buying an additional 1,378 shares during the period. Finally, Soltis Investment Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 4.1% in the 3rd quarter. Soltis Investment Advisors LLC now owns 711 shares of the biopharmaceutical company's stock worth $747,000 after acquiring an additional 28 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating for the company in a research report on Monday. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Finally, UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $964.88.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $8.28 on Wednesday, reaching $549.63. The company's stock had a trading volume of 407,474 shares, compared to its average volume of 979,698. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a market cap of $60.09 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business's fifty day moving average price is $653.75 and its 200 day moving average price is $748.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The company's revenue was up 10.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.